Identifying genetic regulators of hepatic reductive stress in diversity outbred mice
Identifying genetic regulators of hepatic reductive stress in diversity outbred mice
批准号:
10674678
负责人:
Russell Paul Goodman
金额:
$13.01万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-01 至 2024-08-31
关键词:
Biological MarkersBlood GlucoseCytosolDataDiseaseFGF21 geneFacultyFoundationsFutureGeneral HospitalsGenesGeneticGenetic DeterminismGenetic VariationGenomeGenotypeGoalsGrantHeartHepaticHumanHydroxybutyratesLifeLinkLiverMassachusettsMeasurementMeasuresMetabolicMetabolic PathwayMetabolic stressMetabolismMissionMusNADHOrganellesOther GeneticsOxidation-ReductionPathogenesisPhysiologicalPhysiologyPlasmaPopulationPublic HealthReactionResearchResearch Project GrantsSourceStressTestingTissuesTranscriptTriglyceridesUnited States National Institutes of HealthVariantWorkcirculating biomarkerscofactorcohortfatty liver diseasefibroblast growth factor 21gene functiongenetic architecturegenetic variantgenome wide association studyhuman diseasein vivoinnovationinsightliver metabolismmembernew therapeutic targetnoveloxidationtooltraittranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
NADH is a metabolic cofactor that, along with its oxidized form, NAD+, participates in hundreds of
reduction/oxidation (redox) reactions that power cellular metabolism. A relative increase in NADH levels
promotes reduction and is thought to be a source of metabolic stress (“reductive stress”), though the
precise consequences of reductive stress in vivo have been difficult to study due to a lack of tools with
which to precisely manipulate NADH levels. Using a newly developed tool that enables precise tissue-
specific manipulation of NADH, we recently demonstrated that the metabolite -hydroxybutyrate was a
biomarker of hepatic reductive stress, and that hepatic reductive stress was causally linked to a number
of important metabolic traits. The long-term goal of this work to better understand the genetic
architecture of hepatic reductive stress, and in doing so both expand our understanding of its metabolic
and physiologic consequences and to identify potential genes that might be targeted to alter
metabolism in beneficial ways. Our central hypothesis is that genetic regulators of hepatic reductive
stress can be identified in the diversity outbred (DO) mouse cohort by combining existing genotyping
and RNAseq data with measurements of mouse plasma -hydroxybutyrate levels. The rationale for this
proposal is that, having demonstrated that reductive stress influences many important metabolic traits,
identifying genetic regulators of reductive stress will provide key regulators of this important metabolic
parameter and is significant as this will inspire novel therapeutic targeted paradigms. This work is
innovative in that it leverages new insight that plasma -hydroxybutyrate is biomarker of hepatic NADH
levels to use plasma from a genetically diverse mouse cohort to identify causal genetic influences of this
parameter.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An NADH-ChREBP axis in fatty liver disease and dyslipidemia
-
批准号:10564369
-
项目类别:
-
资助金额:$53.78万
-
财政年份:2023
-
负责人:Russell Paul Goodman
-
依托单位:
Identifying genetic regulators of hepatic reductive stress in diversity outbred mice
-
批准号:10354824
-
项目类别:
-
资助金额:$12.99万
-
财政年份:2022
-
负责人:Russell Paul Goodman
-
依托单位:
A METABOLIC BIOMARKER OF HEPATIC NADH/NAD+ RATIO
-
批准号:10221676
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2018
-
负责人:Russell Paul Goodman
-
依托单位:
A METABOLIC BIOMARKER OF HEPATIC NADH/NAD+ RATIO
-
批准号:10456791
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2018
-
负责人:Russell Paul Goodman
-
依托单位:
海外基金